for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Applied Molecular Transport Inc.

AMTI.OQ

Latest Trade

45.82USD

Change

1.38(+3.11%)

Volume

39,402

Today's Range

44.38

 - 

47.17

52 Week Range

17.21

 - 

77.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
44.44
Open
45.11
Volume
39,402
3M AVG Volume
6.18
Today's High
47.17
Today's Low
44.38
52 Week High
77.77
52 Week Low
17.21
Shares Out (MIL)
37.62
Market Cap (MIL)
1,671.89
Forward P/E
-18.16
Dividend (Yield %)
--

Next Event

Applied Molecular Transport Inc at BofA Securities 2021 Healthcare Conference (Virtual)

Latest Developments

More

Applied Molecular Transport Expands Clinical Pipeline And Announces First Subject Dosed In Phase 1A Trial Of Oral AMT-126

Applied Molecular Transport Reports Qtrly Loss Per Share Of $0.48

Applied Molecular Transport Reports Second Quarter 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform including its product candidate, AMT-101, an oral GI-selective rhIL-10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of rhIL-22. The Company’s technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics, with development-stage drugs.

Industry

Biotechnology & Drugs

Contact Info

1 Tower Place, Suite 850

SOUTH SAN FRANCISCO, CA

94080

United States

+1.650.3920420

https://www.appliedmt.com/company/

Executive Leadership

Helen S. Kim

Independent Chairman of the Board

Tahir Mahmood

Chief Executive Officer, Co-Founder, Director

Randall Mrsny

Co-Founder, Chief Scientific Officer, Director

Shawn M. Cross

Chief Financial Officer

Brandon Hants

Senior Vice President - Finance and Business Operations

Key Stats

1.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-2.910

2021(E)

-2.447
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
11.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.48
LT Debt To Equity (MRQ)
0.31
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up